| Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis G Disanto, C Barro, P Benkert, Y Naegelin, S Schädelin, A Giardiello, ... Annals of neurology 81 (6), 857-870, 2017 | 999 | 2017 |
| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 966 | 2018 |
| ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis X Montalban, R Gold, AJ Thompson, S Otero-Romero, MP Amato, ... Multiple Sclerosis Journal 24 (2), 96-120, 2018 | 928 | 2018 |
| Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa J Kuhle, C Barro, U Andreasson, T Derfuss, R Lindberg, Å Sandelius, ... Clinical Chemistry and Laboratory Medicine (CCLM) 54 (10), 1655-1661, 2016 | 675 | 2016 |
| Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment M Krumbholz, D Theil, S Cepok, B Hemmer, P Kivisäkk, RM Ransohoff, ... Brain 129 (1), 200-211, 2006 | 638 | 2006 |
| BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma M Krumbholz, D Theil, T Derfuss, A Rosenwald, F Schrader, ... The Journal of experimental medicine 201 (2), 195-200, 2005 | 568 | 2005 |
| Neurofascin as a novel target for autoantibody-mediated axonal injury EK Mathey, T Derfuss, MK Storch, KR Williams, K Hales, DR Woolley, ... The Journal of experimental medicine 204 (10), 2363-2372, 2007 | 493 | 2007 |
| Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study J Kuhle, G Disanto, R Dobson, R Adiutori, L Bianchi, J Topping, ... Multiple Sclerosis Journal 21 (8), 1013-1024, 2015 | 375 | 2015 |
| Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response D Theil, T Derfuss, I Paripovic, S Herberger, E Meinl, O Schueler, ... The American journal of pathology 163 (6), 2179-2184, 2003 | 358 | 2003 |
| Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis AK Pröbstel, K Dornmair, R Bittner, P Sperl, D Jenne, S Magalhaes, ... Neurology 77 (6), 580-588, 2011 | 342 | 2011 |
| Myelin-oligodendrocyte glycoprotein antibody-associated disease R Marignier, Y Hacohen, A Cobo-Calvo, AK Pröbstel, O Aktas, ... The Lancet Neurology 20 (9), 762-772, 2021 | 330 | 2021 |
| B cells and antibodies in multiple sclerosis pathogenesis and therapy M Krumbholz, T Derfuss, R Hohlfeld, E Meinl Nature Reviews Neurology 8 (11), 613-623, 2012 | 288 | 2012 |
| Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study P Benkert, S Meier, S Schaedelin, A Manouchehrinia, Ö Yaldizli, ... The Lancet Neurology 21 (3), 246-257, 2022 | 285 | 2022 |
| Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals T Derfuss, K Parikh, S Velhin, M Braun, E Mathey, M Krumbholz, ... Proceedings of the National Academy of Sciences 106 (20), 8302-8307, 2009 | 279 | 2009 |
| Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity J Kuhle, C Barro, G Disanto, A Mathias, C Soneson, G Bonnier, Ö Yaldizli, ... Multiple Sclerosis Journal 22 (12), 1550-1559, 2016 | 275 | 2016 |
| Neurofascin as a target for autoantibodies in peripheral neuropathies JKM Ng, J Malotka, N Kawakami, T Derfuss, M Khademi, T Olsson, ... Neurology 79 (23), 2241-2248, 2012 | 274 | 2012 |
| Optimizing treatment success in multiple sclerosis T Ziemssen, T Derfuss, N de Stefano, G Giovannoni, F Palavra, D Tomic, ... Journal of neurology 263, 1053-1065, 2016 | 226 | 2016 |
| Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis A Waschbisch, M Atiya, RA Linker, S Potapov, S Schwab, T Derfuss PloS one 6 (9), e24604, 2011 | 211 | 2011 |
| Multiple sclerosis progression: time for a new mechanism-driven framework T Kuhlmann, M Moccia, T Coetzee, JA Cohen, J Correale, J Graves, ... The Lancet Neurology 22 (1), 78-88, 2023 | 193 | 2023 |
| Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity M Krumbholz, H Faber, F Steinmeyer, LA Hoffmann, T Kümpfel, ... Brain 131 (6), 1455-1463, 2008 | 186 | 2008 |
